As thrombocytopenia (65) and hyperlipidemia (40, 66) are known adverse events in humans treated with rapamycin and other mTOR inhibitors, continued monitoring of these parameters in future studies of rapamycin in dogs is indicated. Here, MTOR is linked to Thrombocytopenia.